Science / Health
New Immunotherapy Shows Promise in Advanced Melanoma Trial
University of Massachusetts researchers report a 62 percent response rate in a 247-patient trial of experimental cancer treatment, though oncologists urge caution about early-stage results.
Researchers at the University of Massachusetts Medical School announced preliminary results from a Phase II clinical trial of a new immunotherapy treatment for advanced melanoma, showing promising response rates that have energized oncologists while drawing measured caution about the therapy's ultimate effectiveness. The trial, which enrolled 247 patients across 19 medical centers, demonstrated a 62 percent response rate after six months of treatment, compared to 38 percent for the standard chemotherapy regimen currently in use.
The experimental drug, known as LN-4827, works by releasing immune checkpoints that prevent the body's own cancer-fighting cells from attacking tumors. Patients in the trial received monthly infusions over a 24-week period, with researchers tracking tumor shrinkage, progression-free survival, and safety outcomes. Lead investigator Dr. Margaret Chen of UMass Medical described the results as "encouraging but far from conclusive at this stage of development."
Managing Side Effects
While the response rate exceeded expectations, adverse events were notable. Forty-three percent of trial participants experienced grade 3 or higher immune-related side effects, including inflammation of the lungs, liver damage, and severe skin reactions. Three patients withdrew from the study due to intolerable toxicity, and two additional patients died from complications attributed to immune-related inflammation, though the research team emphasized that causality remains under investigation. Standard supportive care managed most side effects successfully, but the trial protocol required close monitoring and ready access to corticosteroid therapy.
Years Away From Patients
"This is very early-stage work, and I want to be clear about that," said Dr. James Rodriguez, chief of oncology at Boston Medical Center, who was not involved in the trial. "A 62 percent response rate sounds wonderful in a press release, but we need to see whether these responses are durable, whether overall survival is meaningfully extended, and whether patients actually live longer and better with this drug than with existing options. We're probably three to five years away from knowing whether LN-4827 becomes standard care." Rodriguez noted that response rates in Phase II trials often do not translate to the broader patient population when tested in larger Phase III studies.
The trial's next phase, scheduled to begin in early 2027, will include 600 patients and compare LN-4827 directly to the current standard of care across multiple cancer types, including lung cancer and triple-negative breast cancer. The trial is funded by Nexus Pharmaceuticals, the drug's manufacturer, with additional support from the National Institutes of Health. Researchers expect initial Phase III data within 18 months, though full regulatory review could extend approval timelines by several years if additional safety monitoring is required. The company has not announced pricing for the treatment, which requires monthly administration and regular lab monitoring, suggesting it will be substantially more expensive than current options.